Table 1:

Demographic and clinical characteristics^{^a}

	Controls n = 15	PSP n = 24	CBD n = 9	MSA n = 19	PD n = 18	P Value
Demographic data
Sex (M/F)	8:7	13:11	4:5	14:5	10:8	.454^{^b}
Age (yr)	62.6 (9.0)	63.2 (6.8)	67.9 (5.6)	64.2 (7.1)	64.4 (9.3)	.433^{^c}
Disease duration (yr)	NA	3.3 (1.8)	3.3 (1.8)	3.1 (2.1)	10.6 (6.1)	<.001^{^c}
Clinical data
UPDRS III	NA	21.3 (9.8)	25.2 (7.1)	19.6 (19.1)	32.3 (11.5)	.875^{^c}
UPDRS_brad	NA	6.1 (4.7)	12.5 (3.6)	7.7 (9.3)	14.5 (8.4)	.134^{^c}
UPDRS_rig	NA	4.1 (3.0)	7.2 (4.4)	3.9 (5.6)	9.2 (6.5)	.266^{^c}
White matter lesion burden assessment
Fazekas PVH score	0.38 (0.65)	0.71 (0.75)	0.70 (0.48)	0.37 (0.50)	0.47 (0.62)	.321^{^c}
Fazekas DWMH score	0.77 (0.73)	0.54 (0.66)	0.40 (0.52)	0.53 (061)	0.53 (0.51)	.684^{^c}

Note:—DWMH indicates deep white matter hyperintensity; UPDRS, Unified Parkinson Disease Rating Scale; UPDRS_brad, bradykinesia subscore of UPDRS; UPDRS_rig, rigidity subscore of UPDRS; PVH, periventricular; NA, not applicable.
↵a Data are presented as mean (SD).
↵b χ² test.
↵c ANOVA.